Bacterial vaginosis
Conditions
Interventions
Conventional antibiotic therapy:antibiotic therapy
Conventional antibiotics + oral probiotics:Antibiotic therapy + oral probiotics
Conventional antibiotics + probiotics for vaginal treatment:Antibiotics + vaginal probiotics
Conventional antibiotics + Probiotics vaginal treatment + oral probiotics:antibiotics + vaginal probiotics + oral probiotics
BV case group:None
Healthy control group:None
Sponsors
Ganzhou People 's Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: (1) The inclusion criteria of the normal control group (group C) were as follows: a. healthy women of childbearing age (20-45 years old) with regular menstrual cycles; b. No sexual life, vaginal irrigation and drug use history within 7 days before the examination; c. Vaginal secretions, cervical cancer screening and gynecological color ultrasonography showed no obvious abnormalities; d. No other chronic underlying diseases. (2) Inclusion criteria for bacterial vaginosis (Group B) : it met the diagnostic criteria for BV When diagnosing BV, care should be taken to rule out other common vaginal inflammation mixed infections. At present, the diagnosis of BV is mainly based on Amsel clinical diagnostic criteria and Gram staining Nugent score diagnostic criteria.
Exclusion criteria
Exclusion criteria: 1) Gonorrhea patients, genital herpes, and condyloma acuminatum; 2) Suffering from diseases of the reproductive system and other systems; 3) pregnancy; 4) lactating women; 5) Patients who underwent vaginal douching, spermicide use, and tampons within 7 days prior to treatment. 6) Abnormal HPV and TCT detection; 8) Use systemic drugs; ? Use probiotics (oral or vaginal); 9) Use traditional Chinese medicine or homeopathic medicine; 10) Acute diseases; 11) Tumor history; 12) Positive serological test for HIV, hepatitis C, hepatitis B, or syphilis. 13) History of gastrointestinal disease, autoimmune disease and immunomodulatory therapy, chronic pain and neuropsychiatric disorders, obesity (BMI>30). 14) No history of allergy to probiotics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy and recurrence rate of BV patients before and after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vaginal flora in BV patients and healthy controls;Intestinal flora in BV patients and healthy controls;Changes of vaginal microflora in 4 groups of BV patients before and after treatment;Changes of intestinal flora in 4 groups of BV patients before and after treatment; | — |
Countries
China
Contacts
Public ContactLiu Yan
Ganzhou People 's Hospital
Outcome results
None listed